The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

IPROPLATIN     dichloroplatinum; propan-2-amine; dihydrate

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Iproplatinum [Latin]


High impact information on Iproplatinum [Latin]


Chemical compound and disease context of Iproplatinum [Latin]


Biological context of Iproplatinum [Latin]


Anatomical context of Iproplatinum [Latin]


Associations of Iproplatinum [Latin] with other chemical compounds


Gene context of Iproplatinum [Latin]

  • The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma [26].
  • The results indicate that in patients receiving the drug, the reduction of iproplatin to CIP must take place intracellularly and that CIP or its protein-binding derivatives must efflux from the cells into the plasma [17].
  • Urinary protein and enzyme excretion was measured in 33 patients with solid tumours receiving chemotherapy with the cis-platinum analogs carboplatin (JM8, CBDCA) and iproplatin (JM9, CHIP) [27].
  • Levels of three enzymes, leucine aminopeptidase (LAP), N-acetyl-beta-D-glucosaminidase (NAG), and beta-glucuronidase (BGA) were measured in the urine of patients receiving hematologically toxic doses of iproplatin (a) with or (b) without pretreatment hydration [28].
  • Iproplatin showed relatively marked binding to proteins of higher mol. wt. but no transfer with time to the low mol. wt. protein zone [29].

Analytical, diagnostic and therapeutic context of Iproplatinum [Latin]


  1. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. Trask, C., Silverstone, A., Ash, C.M., Earl, H., Irwin, C., Bakker, A., Tobias, J.S., Souhami, R.L. J. Clin. Oncol. (1991) [Pubmed]
  2. Phase II study of iproplatin in advanced ovarian carcinoma. Sessa, C., Vermorken, J., Renard, J., Kaye, S., Smith, D., ten Bokkel Huinink, W., Cavalli, F., Pinedo, H. J. Clin. Oncol. (1988) [Pubmed]
  3. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. Friedman, H.S., Krischer, J.P., Burger, P., Oakes, W.J., Hockenberger, B., Weiner, M.D., Falletta, J.M., Norris, D., Ragab, A.H., Mahoney, D.H. J. Clin. Oncol. (1992) [Pubmed]
  4. Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. Casper, E.S., Smart, T.C., Hakes, T.B., Ochoa, M., Kaufman, R.J. Investigational new drugs. (1988) [Pubmed]
  5. Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung. Cappelaere, P., Guiochet, N., Bastit, P., Favre, R., Vanderburg, M., Goupil, A., Chauvergne, J., Thomas, D., Van Glabbeke, M., Armand, J.P. Eur. J. Cancer (1993) [Pubmed]
  6. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis. Müller, L.J., Moorer-van Delft, C.M., Roubos, E.W., Vermorken, J.B., Boer, H.H. Cancer Res. (1992) [Pubmed]
  7. Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Pendyala, L., Cowens, J.W., Chheda, G.B., Dutta, S.P., Creaven, P.J. Cancer Res. (1988) [Pubmed]
  8. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Teicher, B.A., Holden, S.A., Kelley, M.J., Shea, T.C., Cucchi, C.A., Rosowsky, A., Henner, W.D., Frei, E. Cancer Res. (1987) [Pubmed]
  9. Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity. Pendyala, L., Madajewicz, S., Creaven, P.J. Cancer Res. (1985) [Pubmed]
  10. Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue. Paolozzi, F.P., Gaver, R., Poiesz, B.J., Louie, A., DiFino, S., Comis, R.L., Newman, N., Ginsberg, S. Investigational new drugs. (1988) [Pubmed]
  11. Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer. Casper, E.S., Curley, T., Hakes, T.B. Investigational new drugs. (1989) [Pubmed]
  12. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids. Russell, J., Adam, J., Wheldon, T.E., Kaye, S.B. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  13. Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. Petrelli, N.J., Creaven, P.J., Herrera, L., Mittelman, A. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  14. The effect of platinum cytostatics on delayed-type hypersensitivity in mice. Jílek, P., Dvoráková, J., Turecková, J., Procházková, J. Neoplasma (1989) [Pubmed]
  15. Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (chip, JM9)]. Chawla, S.P., Yap, B.S., Tenney, D.M., Bodey, G.P., Benjamin, R.S. Investigational new drugs. (1988) [Pubmed]
  16. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Mellish, K.J., Kelland, L.R., Harrap, K.R. Br. J. Cancer (1993) [Pubmed]
  17. Studies on the human metabolism of iproplatin. Pendyala, L., Krishnan, B.S., Walsh, J.R., Arakali, A.V., Cowens, J.W., Creaven, P.J. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  18. Intracellular glutathione and cytotoxicity of platinum complexes. Pendyala, L., Creaven, P.J., Perez, R., Zdanowicz, J.R., Raghavan, D. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  19. Studies on mutagenesis and repair induced by platinum analogs. Fram, R.J., Cusick, P.S., Marinus, M.G. Mutat. Res. (1986) [Pubmed]
  20. An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin. Ewen, C., Perera, A., Hendry, J.H., McAuliffe, C.A., Sharma, H., Fox, B.W. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  21. Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial. Drasga, R.E., Williams, S.D., Einhorn, L.H., Birch, R. Cancer treatment reports. (1987) [Pubmed]
  22. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Hubbard, K.P., Pazdur, R., Ajani, J.A., Braud, E., Blaustein, A., King, M., Llenado-Lee, M., Winn, R., Levin, B., Abbruzzese, J.L. Am. J. Clin. Oncol. (1992) [Pubmed]
  23. Effect of a platinum chemotherapy drug on intracellular elements during the cell cycle, using X-ray microanalysis. Edwards, P.G., Kendall, M.D., Morris, I.W. Scanning Microsc. (1991) [Pubmed]
  24. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Lichtenstein, A.K., Pende, D. Cancer Res. (1986) [Pubmed]
  25. Platinum compounds in the treatment of advanced breast cancer. Martín, M. Clin. Breast Cancer (2001) [Pubmed]
  26. The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Pawinski, A., Crowther, D., Keizer, H.J., Voûte, P.A., Somers, R., van Glabbeke, M., Lentz, M.A., van Oosterom, A.T. Eur. J. Cancer (1999) [Pubmed]
  27. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Skillen, A.W., Buamah, P.K., Cantwell, B.M., Cornell, C., Hodson, A.W., Harris, A.L. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  28. Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes. Pendyala, L., Madajewicz, S., Lele, S.B., Arbuck, S.G., Creaven, P.J. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  29. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Perera, A., Jackson, H., Sharma, H.L., McAuliffe, C.A., Fox, B.W. Chem. Biol. Interact. (1992) [Pubmed]
  30. Evidence that glutathione may determine the differential cell-cycle phase toxicity of a platinum (IV) antitumor agent. Edwards, P.G. J. Natl. Cancer Inst. (1988) [Pubmed]
  31. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Vermorken, J.B., Gundersen, S., Clavel, M., Smyth, J.F., Dodion, P., Renard, J., Kaye, S.B. Ann. Oncol. (1993) [Pubmed]
  32. Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. Murphy, D., Lind, M.J., Prendiville, J., Renninson, J., Smith, D.R., Thompson, G., Ranson, M., Crowther, D. Eur. J. Cancer (1992) [Pubmed]
WikiGenes - Universities